Novel Immunotherapeutics for Treatment of Glioblastoma

The Last Decade of Research

Emaad Khansur, Ashish H. Shah, Kyle Lacy, Ricardo J Komotar

Research output: Contribution to journalArticle

Abstract

Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of immunotherapy has recently identified glioblastoma as a potential target for new treatments. Anti-tumor vaccines (dendritic cell/heat shock), checkpoint inhibitors, chimeric T-cell receptors, and virotherapy all have been preliminarily trialed in glioblastoma patients with reasonable success and safety. Although there are certainly limitations due to autoimmune reactions and immune escape, immunotherapeutics hold much promise in the future treatment paradigms for malignant glioma.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCancer Investigation
Volume37
Issue number1
DOIs
StatePublished - Jan 2 2019
Externally publishedYes

Fingerprint

Glioblastoma
Escape Reaction
Research
Cancer Vaccines
T-Cell Antigen Receptor
Glioma
Immunotherapy
Colonic Neoplasms
Dendritic Cells
Melanoma
Shock
Lung Neoplasms
Therapeutics
Hot Temperature
Safety
Survival
Neoplasms

Keywords

  • Clinical trial
  • Glioblastoma
  • Immunotherapy
  • Novel
  • Outcomes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel Immunotherapeutics for Treatment of Glioblastoma : The Last Decade of Research. / Khansur, Emaad; Shah, Ashish H.; Lacy, Kyle; Komotar, Ricardo J.

In: Cancer Investigation, Vol. 37, No. 1, 02.01.2019, p. 1-7.

Research output: Contribution to journalArticle

Khansur, Emaad ; Shah, Ashish H. ; Lacy, Kyle ; Komotar, Ricardo J. / Novel Immunotherapeutics for Treatment of Glioblastoma : The Last Decade of Research. In: Cancer Investigation. 2019 ; Vol. 37, No. 1. pp. 1-7.
@article{4fcc9f14bb7a4c7f9c29b563805ec8cf,
title = "Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research",
abstract = "Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of immunotherapy has recently identified glioblastoma as a potential target for new treatments. Anti-tumor vaccines (dendritic cell/heat shock), checkpoint inhibitors, chimeric T-cell receptors, and virotherapy all have been preliminarily trialed in glioblastoma patients with reasonable success and safety. Although there are certainly limitations due to autoimmune reactions and immune escape, immunotherapeutics hold much promise in the future treatment paradigms for malignant glioma.",
keywords = "Clinical trial, Glioblastoma, Immunotherapy, Novel, Outcomes",
author = "Emaad Khansur and Shah, {Ashish H.} and Kyle Lacy and Komotar, {Ricardo J}",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/07357907.2018.1479414",
language = "English (US)",
volume = "37",
pages = "1--7",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Novel Immunotherapeutics for Treatment of Glioblastoma

T2 - The Last Decade of Research

AU - Khansur, Emaad

AU - Shah, Ashish H.

AU - Lacy, Kyle

AU - Komotar, Ricardo J

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of immunotherapy has recently identified glioblastoma as a potential target for new treatments. Anti-tumor vaccines (dendritic cell/heat shock), checkpoint inhibitors, chimeric T-cell receptors, and virotherapy all have been preliminarily trialed in glioblastoma patients with reasonable success and safety. Although there are certainly limitations due to autoimmune reactions and immune escape, immunotherapeutics hold much promise in the future treatment paradigms for malignant glioma.

AB - Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of immunotherapy has recently identified glioblastoma as a potential target for new treatments. Anti-tumor vaccines (dendritic cell/heat shock), checkpoint inhibitors, chimeric T-cell receptors, and virotherapy all have been preliminarily trialed in glioblastoma patients with reasonable success and safety. Although there are certainly limitations due to autoimmune reactions and immune escape, immunotherapeutics hold much promise in the future treatment paradigms for malignant glioma.

KW - Clinical trial

KW - Glioblastoma

KW - Immunotherapy

KW - Novel

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=85060052319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060052319&partnerID=8YFLogxK

U2 - 10.1080/07357907.2018.1479414

DO - 10.1080/07357907.2018.1479414

M3 - Article

VL - 37

SP - 1

EP - 7

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 1

ER -